Clinical Edge Journal Scan

Real-world study finds increased remission with fewer corticosteroids and more biologics in RA


 

Key clinical point: Modern management of rheumatoid arthritis (RA) led to a larger proportion of patients achieving remission with fewer corticosteroids and more biologics over a 7-year follow-up period.

Major finding: Twice as many patients with RA were in remission at 7-year follow-up vs. at 1 year. Patients achieving remission at 7 years were more likely to be using biological disease-modifying antirheumatic drugs (DMARD) and conventional DMARD ( P = .02), whereas corticosteroids ( P = .02) at higher doses ( P = .013) were mostly prescribed to patients not achieving remission at 7 years.

Study details: The data come from a retrospective study of 215 patients with RA whose clinical and biological data were analyzed at 1 year (2009) and 7 years (2015).

Disclosures: The authors declared no source of funding or conflicts of interest .

Source: Larid G et al. Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions. Sci Rep. 2022;12:2563 (Feb 15). Doi: 10.1038/s41598-022-06584-y

Recommended Reading

Clinical Edge Journal Scan Commentary: RA March 2022
MDedge Rheumatology
Updated perioperative guidance says when to hold antirheumatics
MDedge Rheumatology
No excess mortality seen in contemporary undifferentiated arthritis
MDedge Rheumatology
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
MDedge Rheumatology
RA: Early pain relief and better quality of life with baricitinib vs. methotrexate
MDedge Rheumatology
Baricitinib prevents joint deterioration independent of disease activity in RA
MDedge Rheumatology
No effect of additional COVID-19 vaccine dose on RA disease activity
MDedge Rheumatology
Satisfactory immune response to PCV-13 in RA patients receiving upadacitinib
MDedge Rheumatology
Predictors of flare following remission and treatment withdrawal in early RA
MDedge Rheumatology
Temporary methotrexate withdrawal boosts anti-SARS-CoV-2 immunogenicity in RA
MDedge Rheumatology